Skip to Content

Tecentriq Approval History

FDA Approved: Yes (First approved May 18, 2016)
Brand name: Tecentriq
Generic name: atezolizumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Bladder Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Small Cell Lung Cancer

Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of advanced urothelial carcinoma; the treatment of metastatic non-small cell lung cancer (NSCLC); extensive-stage small cell lung cancer; and for use in combination with Abraxane for the treatment of metastatic triple-negative breast cancer.

Development History and FDA Approval Process for Tecentriq

DateArticle
Mar 18, 2019Approval FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
Mar  8, 2019Approval FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
Dec  6, 2018Approval FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Apr 17, 2017Approval FDA Grants Genentech’s Tecentriq (atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
Oct 18, 2016Approval FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer
May 18, 2016Approval FDA Approves Tecentriq (atezolizumab) for Urothelial Carcinoma
Apr 10, 2016FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Mar 14, 2016FDA Grants Genentech’s Cancer Immunotherapy Atezolizumab Priority Review for Advanced Bladder Cancer
Jan  8, 2016Roche Presents Updated Results for Investigational Cancer Immunotherapy Atezolizumab in Advanced Bladder Cancer
Aug 26, 2015Syndax Enters Clinical Trial Collaboration In Cancer Immunotherapy Combining Entinostat and Atezolizumab
Aug 16, 2015Pivotal Phase II Study Showed Atezolizumab Shrank Tumors in People with a Specific Type of Lung Cancer
Jul 12, 2015In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide